Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06891742 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Phase I Study of OriC902 in Treatment of Advanced HCC

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
Peking University
118 trials monitored
See 4 trials at risk
Liver Cancer
1,598 trials monitored
See 71 trials at risk
This is a Phase I clinical study evaluating the safety, pharmacokinetics, and initial efficacy of a GPC3-targeted chimeric antigen receptor autologous T cell injection (OriC902) in GPC3-positive advanced hepatocellular carcinoma (HCC) subjects
Trial Details
NCT Number NCT06891742
Lead Sponsor Peking University
Collaborators: OriCell Therapeutics Co., Ltd.
Conditions
(from sponsor)		 HCC
Enrollment 44 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov